Home » Stocks » PRTA

Prothena Corporation PLC (PRTA)

Stock Price: $22.98 USD 1.35 (6.24%)
Updated May 14, 2021 4:00 PM EDT - Market closed
Market Cap 990.42M
Revenue (ttm) 872,000
Net Income (ttm) -124.31M
Shares Out 44.18M
EPS (ttm) -3.11
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 14
Last Price $22.98
Previous Close $21.63
Change ($) 1.35
Change (%) 6.24%
Day's Open 21.63
Day's Range 21.27 - 23.24
Day's Volume 219,547
52-Week Range 9.25 - 28.66

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Prothena (PRTA) reports a wider loss in the first quarter of 2021. The pipeline remains in focus with the planned initiation of three late-stage studies for birtamimab, prasinezumab and PRX004.

2 days ago - Zacks Investment Research

DUBLIN, Ireland, May 11, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of novel investigational therapeutics built on protein dysr...

3 days ago - GlobeNewsWire

Prothena Corporation plc (NASDAQ: PRTA) has dosed the first patient in the Phase 2b PADOVA study evaluating prasinezumab in patients with early Parkinson's disease. Prasinezumab is an anti-alpha synucle...

3 days ago - Benzinga

Let us take a look at four small companies, CPRX, MYOV, PRTA, HRMY, which are gearing up for their earnings release.

Other stocks mentioned: CPRX, HRMY, MYOV
4 days ago - Zacks Investment Research

DUBLIN, Ireland, May 07, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of novel investigational therapeutics built on protein dysr...

1 week ago - GlobeNewsWire

DUBLIN, Ireland, May 04, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational therapeu...

1 week ago - GlobeNewsWire

Prothena (PRTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 weeks ago - Zacks Investment Research

The stock price of Prothena Corporation, a biotechnology company focused on treatment of diseases that involve protein misfolding or cell adhesion, has seen a 9% rise over the last five trading days, af...

3 weeks ago - Forbes

DUBLIN, Ireland, April 18, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA) today presented positive results from the Phase 1 study of PRX004 as part of the Emerging Science Session at th...

3 weeks ago - GlobeNewsWire

DUBLIN, Ireland, April 15, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational therap...

4 weeks ago - GlobeNewsWire

DUBLIN, Ireland, April 07, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational therap...

1 month ago - GlobeNewsWire

Dr. Garren's extensive expertise and successful track record of advancing neurology and rare disease programs through late-stage development, registration and launch supports Company's transition to a f...

1 month ago - GlobeNewsWire

Prothena (PRTA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

1 month ago - Zacks Investment Research

DUBLIN, Ireland, March 24, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational therap...

1 month ago - GlobeNewsWire

DUBLIN, Ireland, March 23, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational therap...

1 month ago - GlobeNewsWire

Prothena (PRTA) reported earnings 30 days ago. What's next for the stock?

2 months ago - Zacks Investment Research

DUBLIN, Ireland, March 08, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational therap...

2 months ago - GlobeNewsWire

DUBLIN, Ireland, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational therape...

2 months ago - GlobeNewsWire

Insider buying can be an encouraging signal for potential investors, especially when markets face uncertainty. Biotech stocks and secondary and initial public offerings were well represented this week.

Other stocks mentioned: BMBL, FISV, ATEX, CRVS, DBTX, MTEM, NEXI ...
2 months ago - Benzinga

Prothena (PRTA) beats on earnings in the fourth quarter of 2020 and surpasses sales estimates too.

3 months ago - Zacks Investment Research

Corvus Pharmaceuticals (NASDAQ: CRVS) shares are trading lower Friday after the company priced its 8.571 million share common stock offering at $3.50 per share. Corvus Pharmaceuticals Inc is a clinical-...

Other stocks mentioned: CRVS, CLGN
3 months ago - Benzinga

Prothena (PRTA) delivered earnings and revenue surprises of 7.23% and 80.00%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

Shares of Prothena Corp (NASDAQ:PRTA) were unchanged after the company reported Q4 results. Quarterly Results Earnings per share decreased 42.59% year over year to ($0.77), which were in line with the e...

3 months ago - Benzinga

DUBLIN, Ireland, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational therape...

3 months ago - GlobeNewsWire

DUBLIN, Ireland, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational therape...

3 months ago - GlobeNewsWire

DUBLIN, Ireland, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a pipeline of investigational therape...

3 months ago - GlobeNewsWire

Prothena (PRTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

DUBLIN, Ireland, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA) today announced that following further analyses by the Company and multiple in-depth discussions with the U.S. F...

3 months ago - GlobeNewsWire

DUBLIN, Ireland, Dec. 04, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a diverse pipeline of investigational...

5 months ago - GlobeNewsWire

Prothena (PRTA) reported earnings 30 days ago. What's next for the stock?

5 months ago - Zacks Investment Research

Prothena (PRTA) misses earnings and sales estimates in the third quarter of 2020.

6 months ago - Zacks Investment Research

Prothena (PRTA) delivered earnings and revenue surprises of -13.24% and -70.54%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

DUBLIN, Ireland, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a diverse pipeline of investigational...

6 months ago - GlobeNewsWire

DUBLIN, Ireland, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a diverse pipeline of investigational...

6 months ago - GlobeNewsWire

DUBLIN, Ireland, Oct. 28, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a diverse pipeline of investigational...

6 months ago - GlobeNewsWire

Prothena (PRTA) and partner Roche (RHHBY) plan to advance prasinezumab into a phase IIb study in patients with early Parkinson's disease.

6 months ago - Zacks Investment Research

DUBLIN, Ireland, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with expertise in protein dysregulation and a diverse pipeline of investigational...

6 months ago - GlobeNewsWire

DUBLIN, Ireland, Oct. 02, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage company with expertise in protein dysregulation and a diverse pipeline of investigational ther...

7 months ago - GlobeNewsWire

DUBLIN, Ireland, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage company with expertise in protein dysregulation and a diverse pipeline of investigational t...

7 months ago - GlobeNewsWire

DUBLIN, Ireland, Sept. 11, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), announced that results from the Phase 2 PASADENA study of prasinezumab are being highlighted today at the In...

8 months ago - GlobeNewsWire

DUBLIN, Ireland, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage company with expertise in protein dysregulation and a diverse pipeline of investigational t...

8 months ago - GlobeNewsWire

Prothena (PRTA) reported earnings 30 days ago. What's next for the stock?

8 months ago - Zacks Investment Research

DUBLIN, Ireland, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage company with expertise in protein dysregulation and a diverse pipeline of investigational t...

8 months ago - GlobeNewsWire

Prothena (PRTA) delivered earnings and revenue surprises of -3.13% and 11.43%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

9 months ago - Zacks Investment Research

DUBLIN, Ireland, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage company with expertise in protein dysregulation and a diverse pipeline of investigational th...

9 months ago - GlobeNewsWire

DUBLIN, Ireland, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage company with expertise in protein dysregulation and a diverse pipeline of investigational th...

9 months ago - GlobeNewsWire

DUBLIN, Ireland, July 30, 2020 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage company with expertise in protein dysregulation and a diverse pipeleine of investigational t...

9 months ago - GlobeNewsWire

Prothena (PRTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

9 months ago - Zacks Investment Research

Prothena (PRTA) saw a big move last session, as its shares jumped nearly 11% on the day, amid huge volumes.

10 months ago - Zacks Investment Research

Prothena (PRTA) delivered earnings and revenue surprises of 1.67% and -37.33%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

About PRTA

Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing PRX002/RG7935 that is in Phase 2 clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, an antibody that is in Phase 1 clinical trial for the treatment of ATTR amyloidosis. Its discovery-stage programs include Tau for treating Alzheimer's disease, frontotemporal dementia, progressive supranuclear palsy, ... [Read more...]

Industry
Biotechnology
Founded
2012
CEO
Gene Kinney
Employees
66
Stock Exchange
NASDAQ
Ticker Symbol
PRTA
Full Company Profile

Financial Performance

In 2020, Prothena's revenue was $853,000, an increase of 4.79% compared to the previous year's $814,000. Losses were -$111.14 million, 43.1% more than in 2019.

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for Prothena stock is "Buy." The 12-month stock price forecast is 31.86, which is an increase of 38.64% from the latest price.

Price Target
$31.86
(38.64% upside)
Analyst Consensus: Buy